ARTICLES BY MATTHEW PILLAR
-
![20_12_BPO_BusBiotech_Social_ep73]( "Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.")
Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.11/28/2021Lumen Bioscience's cofounder and CEO, Brian Finrow, J.D., and EVP of production/development, Craig Behnke, Ph.D., discuss the development of therapeutic proteins from readily available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.
-
![Cleanroom Clean White Facility]( "The Real Threat To Biopharma Supply Chains: Bioprocessing Materials")
The Real Threat To Biopharma Supply Chains: Bioprocessing Materials5/12/2020The COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive.
-
![iStock-479609078]( "Does Gender Disparity In Biotech Really Matter?")
Does Gender Disparity In Biotech Really Matter?8/29/2019Why it does, and how one startup is winning the biotech talent wars with a diversity-centric strategy.
Matthew Pillar
Matthew Pillar is chief editor at Bioprocess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.
Connect with Pillar on LinkedIn at linkedin.com/in/matthewpillar/